Tongjitang

Tongjitang (同济堂) is a Chinese brand associated with traditional Chinese medicine (TCM) and related health products. The brand name is widely recognized in the Chinese pharmaceutical and health supplement market, where it is linked to a range of TCM-based offerings. The evidence available for this dossier is limited to a seed introduction that identifies the subject as a TCM brand; no further details on founding, ownership, or product specifics are provided in the supplied material. As a result, this summary remains brief and does not extend beyond what the evidence supports. The brand operates in the consumer health space, where traditional Chinese medicine products are commonly sold as over-the-counter remedies, supplements, and wellness items. Tongjitang's official website is listed as tjt.com.cn, indicating an active commercial presence. However, without additional sourced information, a more detailed profile cannot be constructed at this time.

The available evidence for Tongjitang (同济堂) is limited to a seed introduction that identifies it as a traditional Chinese medicine (TCM) brand. No founding date, founder, ownership history, or specific corporate events are provided in the supplied material. Consequently, a detailed historical narrative cannot be constructed from the evidence alone. The brand is recognized in the Chinese TCM and health products sector, and its official website (tjt.com.cn) indicates an ongoing commercial operation. Any further historical details would require additional sourced information that is not currently available. This history section therefore remains minimal and reflects only the identity of the subject as a TCM brand.

• 2016

  Systematic Financial Fraud Inflated Revenue by RMB 21.1 Billion; Actual Controller Banned for Life

  From 2016 to 2019, Tongjitang used subsidiaries to fabricate sales and procurement transactions, inflate selling and administrative expenses, and forge bank receipts, among other methods, cumulatively inflating revenue by RMB 21.121 billion and profit by RMB 2.816 billion; there were also controlling shareholder fund occupation, irregular guarantees, and inaccurate disclosure of raised funds. The CSRC listed the case first among its 20 typical enforcement cases in 2022. The company was fined RMB 3 million; actual controllers Zhang Meihua and Li Qing, a married couple, were jointly fined RMB 5 million and banned from the market for life; CFO Wei Junqiao was fined RMB 1 million and banned for 10 years; the company was subsequently delisted.

  Source

Read more

1. 1Systematic Financial Fraud Inflated Revenue by RMB 21.1 Billion; Actual Controller Banned for Lifecsrc.gov.cn
2. 2Systematic Financial Fraud Inflated Revenue by RMB 21.1 Billion; Actual Controller Banned for Lifecsrc.gov.cn
3. 3Systematic Financial Fraud Inflated Revenue by RMB 21.1 Billion; Actual Controller Banned for Lifecsrc.gov.cn